Headache-type adverse effects of NO donors: Vasodilation and beyond

British Journal of Pharmacology

Volumn 160, Issue 1, 2010, Pages 20-35

  Bagdy, G ^a   Riba, P ^a   Kecskemeti V ^a   Chase, D ^b   Juhasz G ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CGRP; Headache; Migraine; NO donors; Vasodilators

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANALGESIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CYCLIC GMP; CYCLOOXYGENASE 2; DICLOFENAC; GLIBENCLAMIDE; GLYCERYL TRINITRATE; IBUPROFEN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MOLSIDOMINE; NAPROXEN; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTAERYTHRITYL TETRANITRATE; POTASSIUM CHANNEL; PROSTAGLANDIN E2; SEROTONIN; SODIUM CHANNEL; SODIUM CHANNEL NAV1.1;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CHANNELOPATHY; CLINICAL TRIAL; CLUSTER HEADACHE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERANCE; EPISODIC TENSION HEADACHE; GENE MUTATION; HEADACHE; HEREDITY; HUMAN; HYPERTENSION; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; TENSION HEADACHE; VASODILATATION;

CALCITONIN GENE-RELATED PEPTIDE; CYCLOOXYGENASE 2; DRUG TOLERANCE; GENETIC PREDISPOSITION TO DISEASE; HEADACHE DISORDERS; HUMANS; ION CHANNELS; MIGRAINE DISORDERS; NITRIC OXIDE DONORS; PROSTAGLANDINS; RISK FACTORS; SEROTONIN; TIME FACTORS; VASODILATION;

EID: 77950927314     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00643.x     Document Type: Review

References (192)

1. Abshagen U (1996). [Controlled clinical studies of tolerance development and dosing problems in nitrate therapy]. Herz 21 (Suppl. 1 23 30.
2. Abshagen U, Sporl-Radun S (1981). First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol 19 : 423 429.
3. Afridi SK, Kaube H, Goadsby PJ (2004). Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110 : 675 680.
4. Afridi S, Kaube H, Goadsby PJ (2005). Occipital activation in glyceryl trinitrate induced migraine with visual aura. J Neurol Neurosurg Psychiatry 76 : 1158 1160.
5. Ahern GP, Hsu SF, Jackson MB (1999). Direct actions of nitric oxide on rat neurohypophysial K+ channels. J Physiol 520 (Pt 1 165 176.
6. Ahern GP, Hsu SF, Klyachko VA, Jackson MB (2000). Induction of persistent sodium current by exogenous and endogenous nitric oxide. J Biol Chem 275 : 28810 28815.
7. Ahern GP, Klyachko VA, Jackson MB (2002). cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 25 : 510 517.
8. Ahlner J, Andersson RG, Torfgard K, Axelsson KL (1991). Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 43 : 351 423.
9. Ahmmed GU, Xu Y, Hong Dong P, Zhang Z, Eiserich J, Chiamvimonvat N (2001). Nitric oxide modulates cardiac Na(+) channel via protein kinase A and protein kinase G. Circ Res 89 : 1005 1013.
10. Akerman S, Goadsby PJ (2007). Dopamine and migraine: biology and clinical implications. Cephalalgia 27 : 1308 1314.
11. Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002a). The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 452 : 223 228.
12. Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002b). Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 137 : 62 68.
13. Akerman S, Williamson DJ, Goadsby PJ (2003). Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. Br J Pharmacol 140 : 558 566.
14. Akerman S, Kaube H, Goadsby PJ (2004). Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309 : 56 63.
15. Albert A (1961). Isosorbide dinitrate in treatment of angina pectoris. Preliminary clinical impression. J Lancet 81 : 112 114.
16. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113 : 296 320.
17. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 209.
18. Anttila V, Kallela M, Oswell G, Kaunisto MA, Nyholt DR, Hamalainen E et al. (2006). Trait components provide tools to dissect the genetic susceptibility of migraine. Am J Human Genetics 79 : 85 99.
19. Armstrong PW, Moe GW (1993). Medical advances in the treatment of congestive heart failure. Circulation 88 : 2941 2952.
20. Ashina M, Bendtsen L, Jensen R, Olesen J (2000). Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 123 (Pt 9 1830 1837. (Pubitemid 30664285)
21. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J (2001). Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. Eur J Neurol 8 : 173 178.
22. Ashki N, Hayes KC, Bao F (2008). The peroxynitrite donor 3-morpholinosydnonimine induces reversible changes in electrophysiological properties of neurons of the guinea-pig spinal cord. Neuroscience 156 : 107 117.
23. Bagdy G (1998). Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann N Y Acad Sci 851 : 357 363.
24. Bagdy G, Szemeredi K, Hill JL, Murphy DL (1988). The serotonin agonist, M-chlorophenylpiperazine, markedly increases levels of plasma catecholamines in the conscious rat. Neuropharmacology 27 : 975 980.
25. Bai CX, Takahashi K, Masumiya H, Sawanobori T, Furukawa T (2004). Nitric oxide-dependent modulation of the delayed rectifier K+ current and the l-type Ca2+ current by ginsenoside Re, an ingredient of Panax ginseng, in guinea-pig cardiomyocytes. Br J Pharmacol 142 : 567 575.
26. Bank J (2001). Migraine with aura after administration of sublingual nitroglycerin tablets. Headache 41 : 84 87.
27. Behrend O, Schwark C, Kunihiro T, Strupp M (1997). Cyclic GMP inhibits and shifts the activation curve of the delayed-rectifier (I[K1]) of type I mammalian vestibular hair cells. Neuroreport 8 : 2687 2690.
28. Bellamy J, Bowen EJ, Russo AF, Durham PL (2006a). Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 23 : 2057 2066.
29. Bellamy JL, Cady RK, Durham PL (2006b). Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46 : 24 33.
30. Bellantonio P, Micieli G, Buzzi MG, Marcheselli S, Castellano AE, Rossi F et al. (1997). Haemodynamic correlates of early and delayed responses to sublingual administration of isosorbide dinitrate in migraine patients: a transcranial Doppler study. Cephalalgia 17 : 183 187.
31. Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, MaassenVanDenBrink A et al. (2006). Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 24 : 1517 1534.
32. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA (1994). Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368 : 850 853.
33. Brandes JL (2008). The migraine cycle: patient burden of migraine during and between migraine attacks. Headache 48 : 430 441.
34. Brunton TL (1867). Use of nitrate of amyl in angina pectoris. Lancet 2 : 628 629.
35. Bussmann WD, Kaltenbach M (1976). Sublingual nitroglycerin in the treatment of left ventricular failure and pulmonary edema. Eur J Cardiol 4 : 327 333.
36. Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM (2007). Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 28 : 188 195.
37. Cao YQ, Piedras-Renteria ES, Smith GB, Chen G, Harata NC, Tsien RW (2004). Presynaptic Ca2+ channels compete for channel type-preferring slots in altered neurotransmission arising from Ca2+ channelopathy. Neuron 43 : 387 400.
38. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J (1999). Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 19 : 660 667. discussion 626.
39. Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J (2000a). Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. Eur J Neurol 7 : 405 411.
40. Christiansen I, Iversen HK, Olesen J (2000b). Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia 20 : 437 444.
41. Christiansen I, Iversen HK, Olesen J, Tfelt-Hansen P (2008). Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain 9 : 215 220.
42. Colditz GA, Halvorsen KT, Goldhaber SZ (1988). Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am Heart J 116 (1 Pt 1 174 180.
43. Csont T, Ferdinandy P (2005). Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105 : 57 68.
44. Daiber A, Wenzel P, Oelze M, Munzel T (2008). New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 97 : 12 20.
45. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC (2007). Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci 28 : 220 228.
46. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L et al. (2003). Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nature Genetics 33 : 192 196.
47. Dewar HA, Horler AR, Newell DJ (1959). A clinical trial of penta-erythritol tetranitrate, a khellin derivative (recordil), and iproniazid in angina of effort. Br Heart J 21 : 315 322.
48. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S et al. (2005). Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366 : 371 377.
49. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A et al. (2004). Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44 : 414 425.
50. Doerner D, Alger BE (1988). Cyclic GMP depresses hippocampal Ca2+ current through a mechanism independent of cGMP-dependent protein kinase. Neuron 1 : 693 699.
51. Dong DL, Yue P, Yang BF, Wang WH (2008). Hydrogen peroxide stimulates the Ca(2+)-activated big-conductance K channels (BK) through cGMP signaling pathway in cultured human endothelial cells. Cell Physiol Biochem 22 : 119 126.
52. Dong H, Waldron GJ, Cole WC, Triggle CR (1998). Roles of calcium-activated and voltage-gated delayed rectifier potassium channels in endothelium-dependent vasorelaxation of the rabbit middle cerebral artery. Br J Pharmacol 123 : 821 832.
53. Doods H, Arndt K, Rudolf K, Just S (2007). CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 28 : 580 587.
54. Dupuis J (1994). Nitrates in congestive heart failure. Cardiovasc Drugs Ther 8 : 501 507.
55. Dyachenko V, Rueckschloss U, Isenberg G (2009). Modulation of cardiac mechanosensitive ion channels involves superoxide, nitric oxide and peroxynitrite. Cell Calcium 45 : 55 64.
56. Ebright GE (1914). The effects of nitroglycerin on those engaged in its manufacture. JAMA 62 : 201.
57. Edvinsson L (2008). CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 155 : 967 969.
58. Ekbom K, Sjostrand C, Svensson DA, Waldenlind E (2004). Periods of cluster headache induced by nitrate therapy and spontaneous remission of angina pectoris during active clusters. Cephalalgia 24 : 92 98.
59. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P (2008). Vasodilators in the management of acute heart failure. Crit Care Med 36 (1 Suppl S95 105.
60. EMC Electronic Medicines Compendium UK (2010). http://emc.medicines.org. uk (accessed October 2010).
61. Esplugues JV (2002). NO as a signalling molecule in the nervous system. Br J Pharmacol 135 : 1079 1095.
62. Evans JR, Bielefeldt K (2000). Regulation of sodium currents through oxidation and reduction of thiol residues. Neuroscience 101 : 229 236.
63. Evers S (2008). Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 9 : 2565 2573.
64. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al. (2006). EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 13 : 560 572.
65. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S (1995). Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60 : 119 123.
66. Fanciullacci M, Alessandri M, Sicuteri R, Marabini S (1997). Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. Brain 120 (Pt 2 283 288.
67. Ferdinandy P (2006). Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 148 : 1 3.
68. Ferrari MD, Goadsby PJ (2006). Migraine as a cerebral ionopathy with abnormal central sensory processing. In : Gilman S, Pedley T (eds). Neurobiology of Disease. Elsevier
69. Fischera M, Marziniak M, Gralow I, Evers S (2008). The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 28 : 614 618.
70. Fischmeister R, Mery PF (1996). Regulation of cardiac calcium channels by cGMP and NO. In : Morad M, Ebashi S, Trautwein W, Kurachi Y (eds.). Molecular Physiology and Pharmacology of Cardiac Ion Channels and Transporters. Kluwer Acad. Publ
71. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G et al. (1995). Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15 : 384 390.
72. Gargus JJ, Tournay A (2007). Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3. Pediatr Neurol 37 : 407 410.
73. Garthwaite J (2008). Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 27 : 2783 2802.
74. Ghatta S, Nimmagadda D, Xu X, O'Rourke ST (2006). Large-conductance, calcium-activated potassium channels: structural and functional implications. Pharmacol Ther 110 : 103 116.
75. Goadsby PJ (2006a). Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opinion Emerg Drugs 11 : 419 427.
76. Goadsby PJ (2006b). Recent advances in the diagnosis and management of migraine. BMJ 332 : 25 29.
77. Goadsby PJ (2007a). Emerging therapies for migraine. Nat Clin Pract Neurol 3 : 610 619.
78. Goadsby PJ (2007b). Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13 : 39 44.
79. Goadsby PJ, Edvinsson L (1994). Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117 (Pt 3 427 434.
80. Goadsby PJ, Edvinsson L, Ekman R (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurology 28 : 183 187.
81. Gomez R, Nunez L, Vaquero M, Amoros I, Barana A, de Prada T et al. (2008). Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). Cardiovasc Res 80 : 375 384.
82. Gomez R, Caballero R, Barana A, Amoros I, Calvo E, Lopez JA et al. (2009). Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. Circ Res 105 : 383 392.
83. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J (2007). Role of BK(Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat. Cephalalgia 27 : 1120 1127.
84. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J (2008). Role of K ATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. Headache 48 : 1202 1213.
85. Greco R, Tassorelli C, Armentero MT, Sandrini G, Nappi G, Blandini F (2008a). Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Res 1238 : 215 223.
86. Greco R, Tassorelli C, Sandrini G, Di Bella P, Buscone S, Nappi G (2008b). Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia 28 : 114 126.
87. Gribkoff VK (2008). The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update. Expert Opin Ther Targets 12 : 565 581.
88. Gupta MX, Silberstein SD, Young WB, Hopkins M, Lopez BL, Samsa GP (2007). Less is not more: underutilization of headache medications in a university hospital emergency department. Headache 47 : 1125 1133.
89. Hamel E (2007). Serotonin and migraine: biology and clinical implications. Cephalalgia 27 : 1293 1300.
90. Hammarstrom AK, Gage PW (1999). Nitric oxide increases persistent sodium current in rat hippocampal neurons. J Physiolo 520 (Pt 2 451 461.
91. Han J, Kim N, Kim E, Ho WK, Earm YE (2001). Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes. J Biol Chem 276 : 22140 22147.
92. Hans M, Luvisetto S, Williams ME, Spagnolo M, Urrutia A, Tottene A et al. (1999). Functional consequences of mutations in the human alpha1A calcium channel subunit linked to familial hemiplegic migraine. J Neurosci 19 : 1610 1619.
93. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J et al. (2006). Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26 : 992 1003.
94. Hansen JM, Pedersen D, Larsen VA, Sanchez-del-Rio M, Alvarez Linera JR, Olesen J et al. (2007). Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. Cephalalgia 27 : 118 127.
95. Hansen JM, Thomsen LL, Marconi R, Casari G, Olesen J, Ashina M (2008a). Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia 28 : 367 375.
96. Hansen JM, Thomsen LL, Olesen J, Ashina M (2008b). Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 28 : 496 505.
97. Headache Classification Subcommittee of the International Headache Society (2004). The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (Suppl 1 9 160.
98. Held P (1992). Effects of nitrates on mortality in acute myocardial infarction and in heart failure. Br J Clin Pharmacol 34 (Suppl. 1 25S 28S.
99. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I (2006). Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 295 : 1404 1411.
100. Hirooka K, Kourennyi DE, Barnes S (2000). Calcium channel activation facilitated by nitric oxide in retinal ganglion cells. J Neurophysiol 83 : 198 206.
101. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L (2001). 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 909 : 112 120.
102. Hsi DH, Roshandel A, Singh N, Szombathy T, Meszaros ZS (2005). Headache response to glyceryl trinitrate in patients with and without obstructive coronary artery disease. Heart (Br Cardiac Soc) 91 : 1164 1166.
103. Hu H, Chiamvimonvat N, Yamagishi T, Marban E (1997). Direct inhibition of expressed cardiac l-type Ca2+ channels by S-nitrosothiol nitric oxide donors. Circ Res 81 : 742 752.
104. Ignarro LJ, Napoli C, Loscalzo J (2002). Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90 : 21 28.
105. Iversen HK (1995). Experimental headache in humans. Cephalalgia 15 : 281 287.
106. Iversen HK, Olesen J (1996). Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 16 : 412 418.
107. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P (1990). Arterial responses during migraine headache. Lancet 336 : 837 839.
108. Jansen E, Klepzig H (1976). [Studies on the influence of Molsidomin on coronary heart disease (author's transl)]. Med Klin 71 : 2072 2076.
109. Jeng CJ, Chen YT, Chen YW, Tang CY (2006). Dominant-negative effects of human P/Q-type Ca2+ channel mutations associated with episodic ataxia type 2. Am J Physiol 290 : C1209 C1220.
110. Jugdutt BI (1994). Nitrates in myocardial infarction. Cardiovasc Drugs Ther 8 : 635 646.
111. Juhasz G, Zsombok T, Laszik A, Jakus R, Faludi G, Sotonyi P et al. (2003a). Despite the general correlation of the serotonin transporter gene regulatory region polymorphism (5-HTTLPR) and platelet serotonin concentration, lower platelet serotonin concentration in migraine patients is independent of the 5-HTTLPR variants. Neurosci Lett 350 : 56 60.
112. Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J et al. (2003b). NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106 : 461 470.
113. Juhasz G, Zsombok T, Gonda X, Bagdy G (2004). [Nitroglycerin-induced headaches]. Orv Hetil 145 : 2323 2328.
114. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G (2005). Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 25 : 179 183.
115. Juhasz G, Zsombok T, Gonda X, Nagyne N, Modosne E, Bagdy G (2007). Effects of autogenic training on nitroglycerin-induced headaches. Headache 47 : 371 383.
116. Juhasz G, Lazary J, Chase D, Pegg E, Downey D, Toth ZG et al. (2009). Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett 461 : 116 120.
117. Kang M, Ross GR, Akbarali HI (2007). COOH-terminal association of human smooth muscle calcium channel Ca(v)1.2b with Src kinase protein binding domains: effect of nitrotyrosylation. Am J Physiol 293 : 1983 1990.
118. Kawai F, Miyachi E (2001). Modulation by cGMP of the voltage-gated currents in newt olfactory receptor cells. Neurosc Res 39 : 327 337.
119. Klyachko VA, Ahern GP, Jackson MB (2001). cGMP-mediated facilitation in nerve terminals by enhancement of the spike afterhyperpolarization. Neuron 31 : 1015 1025.
120. Kruuse C, Thomsen LL, Birk S, Olesen J (2003). Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126 (Pt 1 241 247.
121. van der Kuy PH, Lohman JJ (2003). The role of nitric oxide in vascular headache. Pharm World Sci 25 : 146 151.
122. Lang RJ, Watson MJ (1998). Effects of nitric oxide donors, S-nitroso-L-cysteine and sodium nitroprusside, on the whole-cell and single channel currents in single myocytes of the guinea-pig proximal colon. Br J Pharmacol 123 : 505 517.
123. Li Z, Chapleau MW, Bates JN, Bielefeldt K, Lee HC, Abboud FM (1998). Nitric oxide as an autocrine regulator of sodium currents in baroreceptor neurons. Neuron 20 : 1039 1049.
124. Lipton RB, Bigal ME (2007). Ten lessons on the epidemiology of migraine. Headache 47 (Suppl. 1 S2 S9.
125. Liu ZW, Lei T, Zhang T, Yang Z (2007). Peroxynitrite donor impairs excitability of hippocampal CA1 neurons by inhibiting voltage-gated potassium currents. Toxicol Lett 175 : 8 15.
126. Loder E, Rizzoli P (2008). Tension-type headache. BMJ 336 : 88 92.
127. van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD (2007). Migraine: gene mutations and functional consequences. Curr Opin Neurol 20 : 299 305.
128. Magis D, Bendtsen L, Goadsby PJ, May A, Sanchez del Rio M, Sandor PS et al. (2007). Evaluation and proposal for optimization of neurophysiological tests in migraine: part 2 - neuroimaging and the nitroglycerin test. Cephalalgia 27 : 1339 1359.
129. Martelletti P, Farinelli I, Steiner TJ (2008). Acute migraine in the Emergency Department: extending European principles of management. Intern Emerg Med 3 (Suppl. 1 S17 S24.
130. Mayer B, Beretta M (2008). The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles. Br J Pharmacol 155 : 170 184.
131. Mehrotra S, Gupta S, Chan KY, Villalon CM, Centurion D, Saxena PR et al. (2008). Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol 378 : 371 394.
132. Meldrum BS, Rogawski MA (2007). Molecular targets for antiepileptic drug development. Neurotherapeutics 4 : 18 61.
133. Miceli F, Soldovieri MV, Martire M, Taglialatela M (2008). Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 8 : 65 74.
134. ® Healthcare Series [Internet Database]. Thomson Reuters (Healthcare)
135. Moncada S, Palmer RM, Higgs EA (1988). The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 12 : 365 372.
136. Montagna P (2008). The primary headaches: genetics, epigenetics and a behavioural genetic model. J Headache Pain 9 : 57 69.
137. Moreno H, Vega-Saenz de Miera E, Nadal MS, Amarillo Y, Rudy B (2001). Modulation of Kv3 potassium channels expressed in CHO cells by a nitric oxide-activated phosphatase. J Physiol 530 (Pt 3 345 358.
138. Mueller RA, Meienberg O (1983). Hemicrania with oculosympathetic paresis from isosorbide dinitrate. N Engl J Med 308 : 458 459.
139. Nardi A, Olesen SP (2008). BK channel modulators: a comprehensive overview. Current Medicinal Chem 15 : 1126 1146.
140. Nunez L, Vaquero M, Gomez R, Caballero R, Mateos-Caceres P, Macaya C et al. (2006). Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovasc Res 72 : 80 89.
141. Olesen J (2008). The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120 : 157 171.
142. Olesen J, Iversen HK, Thomsen LL (1993). Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4 : 1027 1030. (Pubitemid 23242637)
143. Ophoff RA, Terwindt GM, Frants RR, Ferrari MD (1998). P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy. Trends Pharmacol Sci 19 : 121 127.
144. Page IH, Corcoran AC, Dustan HP, Koppanyi T (1955). Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 11 : 188 198.
145. Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J (2000). Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11 : 3071 3075.
146. Parker JA (1996). Organic nitrates: new formulations and their clinical advantages. Am J Cardiol 77 : 38C 40C.
147. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH (2004). Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24 : 735 739.
148. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C et al. (1998). Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17 : 3045 3051.
149. Pharmindex (2008). CMPMedica
150. Pietrobon D (2005). Migraine: new molecular mechanisms. Neuroscientist 11 : 373 386.
151. Pietrobon D (2007). Familial hemiplegic migraine. Neurotherapeutics 4 : 274 284.
152. Prast H, Philippu A (2001). Nitric oxide as modulator of neuronal function. Prog Neurobiol 64 : 51 68.
153. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008). Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28 : 226 236.
154. Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R et al. (2001). Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 124 (Pt 12 2490 2502.
155. Roh S, Choi S, Lim I (2007). Involvement of protein kinase A in nitric oxide stimulating effect on a BK(Ca) channel of human dermal fibroblasts. J Invest Dermatol 127 : 2533 2538.
156. Russell MB (2007). Genetics in primary headaches. J Headache Pain 8 : 190 195.
157. Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G (2004). Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 24 : 110 119.
158. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V (2000). Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20 : 907 918.
159. Scheidt S (1990). Angina: evolution of the role of nitrates. Am Heart J 120 : 757 761 discussion 769-772.
160. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD (2008). Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 131 (Pt 8 2192 2200.
161. Segal MM, Douglas AF (1997). Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 77 : 3021 3034.
162. Shin JH, Chung S, Park EJ, Uhm DY, Suh CK (1997). Nitric oxide directly activates calcium-activated potassium channels from rat brain reconstituted into planar lipid bilayer. FEBS Lett 415 : 299 302.
163. Silberstein SD (2004). Migraine. Lancet 363 : 381 391.
164. Sobey CG (2001). Potassium channel function in vascular disease. Arterioscler Thromb Vasc Biol 21 : 28 38.
165. Srikiatkhachorn A, Anuntasethakul T, Maneesri S, Phansuwan-Pujito P, Patumraj S, Kasantikul V (2000). Hyposerotonin-induced nitric oxide supersensitivity in the cerebral microcirculation. Headache 40 : 267 275.
166. Srikiatkhachorn A, Suwattanasophon C, Ruangpattanatawee U, Phansuwan-Pujito P (2002). 2002 Wolff Award. 5 -HT2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks. Headache 42 : 566 574.
167. Storer RJ, Akerman S, Goadsby PJ (2004). Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142 : 1171 1181.
168. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A et al. (2007). The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27 : 193 210.
169. Tagliaferro P, Ramos AJ, Lopez-Costa JJ, Lopez EM, Saavedra JP, Brusco A (2001). Increased nitric oxide synthase activity in a model of serotonin depletion. Brain Res Bull 54 : 199 205.
170. Taglialatela M, Pannaccione A, Iossa S, Castaldo P, Annunziato L (1999). Modulation of the K(+) channels encoded by the human ether-a-gogo-related gene-1 (hERG1) by nitric oxide. Mol Pharmacol 56 : 1298 1308.
171. Tassorelli C, Costa A, Blandini F, Joseph SA, Nappi G (2000). Effect of nitric oxide donors on the central nervous system - nitroglycerin studies in the rat. Func Neurol 15 (Suppl. 3 19 27.
172. Tassorelli C, Greco R, Armentero MT, Blandini F, Sandrini G, Nappi G (2007). A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin. Int Rev Neurobiol 82 : 373 382.
173. Thadani U (1997). Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther 11 (Suppl. 1 213 218.
174. Thadani U, Ripley TL (2007). Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. Expert Opin Drug Saf 6 : 385 396.
175. Thadani U, Rodgers T (2006). Side effects of using nitrates to treat angina. Expert Opin Drug Saf 5 : 667 674.
176. Thadani U, de Vane PJ (1992). Efficacy of isosorbide mononitrate in angina pectoris. Am J Cardiol 70 : 67G 71G.
177. Thomsen LL, Olesen J (1997). A pivotal role of nitric oxide in migraine pain. Ann N Y Acad Sci 835 : 363 372. (Pubitemid 28046119)
178. Tjong YW, Jian K, Li M, Chen M, Gao TM, Fung ML (2007). Elevated endogenous nitric oxide increases Ca2+ flux via l-type Ca2+ channels by S-nitrosylation in rat hippocampal neurons during severe hypoxia and in vitro ischemia. Free Radic Biol Med 42 : 52 63.
179. Tjong YW, Li M, Hung MW, Wang K, Fung ML (2008). Nitric oxide deficit in chronic intermittent hypoxia impairs large conductance calcium-activated potassium channel activity in rat hippocampal neurons. Free Radic Biol Med 44 : 547 557. (Pubitemid 351181263)
180. Tottene A, Fellin T, Pagnutti S, Luvisetto S, Striessnig J, Fletcher C et al. (2002). Familial hemiplegic migraine mutations increase Ca(2+) influx through single human CaV2.1 channels and decrease maximal CaV2.1 current density in neurons. Proc Natl Acad Sci USA 99 : 13284 13289.
181. Tottene A, Pivotto F, Fellin T, Cesetti T, Maagdenberg AM, Pietrobon D (2005). Specific kinetic alterations of human CaV2.1 calcium channels produced by mutation S218L causing familial hemiplegic migraine and delayed cerebral edema and coma after minor head trauma. J Biol Chem 280 : 17678 17686. (Pubitemid 41389004)
182. Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J (2004). The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 24 : 576 585. (Pubitemid 39272958)
183. Uberbacher HJ, Steinorth G, Glocke M, Abshagen U (1983). An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide 5-mononitrate at low doses in patients with coronary heart disease. Pharmatherapeutica 3 : 331 341. (Pubitemid 13153463)
184. Vanmolkot KR, Terwindt GM, Frants RR, Haan J, Maagdenberg AM, Ferrari MD
185. Weitzman D (1953). Penta-erythritol tetranitrate in treatment of angina. Br Med J 2 : 1409 1412.
186. Wessman M, Terwindt GM, Kaunisto MA, Palotie A, Ophoff RA (2007). Migraine: a complex genetic disorder. Lancet Neurol 6 : 521 532. (Pubitemid 46734771)
187. White RE (1999). Cyclic GMP and ion channel regulation. Adv Second Messenger Phosphoprotein Res 33 : 251 277.
188. Xiao Y, Richter JA, Hurley JH (2008). Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain 4 : 12. (Pubitemid 351622384)
189. Yoshimura N, Seki S, de Groat WC (2001). Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 86 : 304 311. (Pubitemid 32623235)
190. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP (1996). NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci USA 93 : 10489 10494. (Pubitemid 26314650)
191. Yusuf S, Collins R, MacMahon S, Peto R (1988). Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1 : 1088 1092.
192. Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R et al. (2008). CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 155 : 1093 1103.